Akcea Therapeutics
145 articles with Akcea Therapeutics
-
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
-
Clinical Catch-Up: November 22-26
11/29/2021
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look. -
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
-
Ionis Pharmaceuticals unleashed a string of news releases about activities at the company, including a partnership with Progenity and the launch of a Phase III trial for amyotrophic lateral sclerosis.
-
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
10/30/2020
Ionis Pharmaceuticals, Inc. and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of TEGSEDI, the first and only self-administered, subcutaneous treatment for the polyneuropathy of hereditary ATTR amyloidosis in adults.
-
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
10/12/2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. (NASDAQ: AKCA). The combination of Ionis and Akcea accelerates the next phase of Ionis' gr
-
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
-
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
8/31/2020
Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash
-
Shares of Akcea Therapeutics were up more than 58% in premarket trading after its majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24% of available stock for $18.50 per share.
-
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
8/29/2020
Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent reductions in triglyceride levels, apoC-III, and significant reductions in atherogenic lipoproteins
-
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
8/29/2020
Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to placebo
-
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
8/24/2020
Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease
-
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
8/18/2020
Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease
-
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
8/13/2020
WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in Europe
-
Akcea Reports Financial Results and Highlights for Second Quarter 2020
8/4/2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020.
-
BioSpace Movers & Shakers, July 24
7/24/2020
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
7/22/2020
TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Austria for at-home subcutaneous injection TEGSEDI is now commercially available in 15 countries
-
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
7/21/2020
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.
-
Akcea Appoints New Senior Vice President, Global Medical Affairs
7/20/2020
Dr. Christophe Hotermans joins company, with a decade of clinical practice and 12 years of experience in global biotechnology sector.
-
BioSpace Movers & Shakers, July 10
7/10/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.